•  
  •  
  •  
  •  

2023-02-08 09:23:09

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Caprihans India Ltd posts loss in Q3FY23
  • NHPC Ltd posts consolidated PAT of Rs. 671.67 crores in Q3 FY2023
  • Centum Electronics Ltd consolidated Q3 FY2022-23 loss at Rs. 9.66 crores
  • RIR Power Electronics Ltd reports Rs. 2.27 crore net profit in Q3 FY2023
  • Transcorp International Ltd Q3FY23 consolidated profit at Rs. 15.63 lakhs

Keywords Selected:  ZydusLifesciences

Stock Report

  • Zydus Lifesciences Ltd Q3 FY23 consolidated PAT higher at Rs. 622.9 crores
  • Zydus Lifesciences Ltd successfully completes USFDA inspection at Moraiya facility
  • Zydus receives tentative approval from the USFDA for Levomilnacipran Extended-Release Capsules
  • Zydus receives final approval and 180 days shared exclusivity from the USFDA for Brexpiprazole Tablets
  • Zydus receives final approval from the USFDA for Febuxostat Tablets
  • Zydus launches Topiramate Extended-Release Capsules
  • Zydus receives final approval from the USFDA for Triazolam Tablets
  • Zydus receives final approval and 180 days shared exclusivity from the USFDA for Selexipag Tablets
  • Zydus receives two final approvals from the USFDA for Silodosin capsules and Pregabalin capsules
  • Zydus receives final approval from the USFDA for Estradiol Transdermal System which will be manufactured at the Moraiya plant
  • Zydus receives final approval from the USFDA for Topiramate Extended-Release Capsules
  • Zydus Lifesciences Ltd enters into BTA for purchase from Watson Pharma Pvt Ltd
  • Zydus receives tentative approval from the USFDA for Levothyroxine Sodium for Injection
  • Zydus receives final approval from the USFDA for Famotidine Injection
  • Zydus Lifesciences gets exclusive marketing rights for CanAssist Breast
  • Zydus receives final approval from the USFDA for Bisoprolol Fumarate and Hydrochlorothiazide Tablets
  • Zydus receives EIR with VAI from USFDA for its Moraiya formulations manufacturing facility
  • Zydus receives final approval from the USFDA for Acetaminophen injection
  • Zydus receives final approval from the USFDA for Micafungin for Injection
  • Zydus receives tentative approval from the USFDA for Roflumilast Tablets
  • Zydus receives tentative approval from the USFDA for Valbenazine Capsules
  • Zydus receives final approval from USFDA and 180 days shared exclusivity for Brivaracetam Tablets
  • Zydus receives tentative approval from the USFDA for Amantadine Extended-Release Capsules
  • Zydus receives final approval from USFDA and 180 days shared exclusivity for Mirabegron Extended-Release Tablets

Latest Post

  • Caprihans India Ltd posts loss in Q3FY23
  • NHPC Ltd posts consolidated PAT of Rs. 671.67 crores in Q3 FY2023
  • Centum Electronics Ltd consolidated Q3 FY2022-23 loss at Rs. 9.66 crores
  • RIR Power Electronics Ltd reports Rs. 2.27 crore net profit in Q3 FY2023
  • Transcorp International Ltd Q3FY23 consolidated profit at Rs. 15.63 lakhs


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
No:AP-172, 2nd Sector, 10th Street, KK Nagar
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-80560-88967
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

Disclaimer Copyright © - 2022